Ziv-aflibercept

Names

[ CAS No. ]:
1609655-49-3

[ Name ]:
Ziv-aflibercept

Biological Activity

[Description]:

Ziv-aflibercept is a soluble inhibitor of vascular endothelial growth factor (VEGF). Ziv-aflibercept is an adaptive variant of Aflibercept (HY-108801), Ziv-aflibercept has a low PH value and high osmotic pressure when compared to Aflibercept. Ziv-aflibercept has potential applications in metastatic colorectal carcinoma and retinal diseases[1][2].

[Related Catalog]:

Research Areas >> Cancer
Research Areas >> Cardiovascular Disease
Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

[In Vitro]

Ziv-aflibercept (0.25、0.5、1.0 和 5 mg/mL；24 h) 以剂量依赖性方式降低 ARPE-19 细胞的线粒体膜电位[1]。 Cell Viability Assay[1] Cell Line: ARPE-19 cells. Concentration: 0.25, 0.5, 1.0 and 5 mg/mL. Incubation Time: 24 h. Result: Insignificantly affected cell viability (below 1 mg/mL).

[In Vivo]

Ziv-aflibercept (25 mg/mL；眼内注射；单剂量) 在兔子右眼中没有显著引起白内障、视网膜脱离等相关并发症[2]。

[References]

[1]. Malik D, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. Br J Ophthalmol. 2014 Jun;98 Suppl 1(Suppl 1):i11-16.  

[2]. de Oliveira Dias JR, et al. Fusion proteins for treatment of retinal diseases: aflibercept, ziv-aflibercept, and conbercept. Int J Retina Vitreous. 2016 Feb 1;2:3.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.